Castle Biosciences (NASDAQ:CSTL) Insider Sells $108,767.04 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 3,288 shares of the company’s stock in a transaction that occurred on Monday, October 26th. The shares were sold at an average price of $33.08, for a total value of $108,767.04. Following the completion of the sale, the insider owned 45,431 shares in the company, valued at $1,502,857.48. The trade was a 6.75% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Castle Biosciences stock opened at $37.16 on Friday. The firm has a 50 day moving average price of $34.22 and a two-hundred day moving average price of $28.68. The company has a debt-to-equity ratio of 0.02, a quick ratio of 5.85 and a current ratio of 6.04. Castle Biosciences, Inc. has a 52-week low of $17.72 and a 52-week high of $44.28.

Castle Biosciences (NASDAQ:CSTL) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.41) by $0.34. The company had revenue of $99.86 million during the quarter, compared to analysts’ expectations of $86.23 million. Castle Biosciences had a negative net margin of 5.43% and a negative return on equity of 4.15%. As a group, equities research analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on CSTL. BTIG Research boosted their price target on Castle Biosciences from $40.00 to $44.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Robert W. Baird set a $36.00 price target on Castle Biosciences in a research note on Friday, July 31st. Wall Street Zen cut Castle Biosciences from a “buy” rating to a “hold” rating in a research note on Saturday, October 24th. Mizuho assumed coverage on Castle Biosciences in a research report on Thursday. They set an “outperform” rating and a $60.00 target price on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Castle Biosciences in a report on Thursday. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $44.25.

Institutional Investors Weigh In On Castle Biosciences

Large investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. purchased a new stake in Castle Biosciences during the third quarter worth about $55,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Castle Biosciences by 15.5% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 5,574 shares of the company’s stock worth $194,000 after purchasing an additional 747 shares during the last quarter. NFSG Corp bought a new position in Castle Biosciences during the third quarter valued at $36,000. Green Alpha Advisors LLC grew its holdings in Castle Biosciences by 39.1% during the third quarter. Green Alpha Advisors LLC now owns 13,828 shares of the company’s stock valued at $491,000 after purchasing an additional 3,887 shares during the period. Finally, Tidal Investments LLC bought a new stake in shares of Castle Biosciences in the second quarter valued at $529,000. 92.60% of the stock is owned by hedge funds and other institutional investors.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company that develops and commercializes tests designed to help physicians diagnose cancer, assess disease risk and guide treatment decisions. The company focuses on conditions in which additional biological information can complement traditional pathology and clinical assessment.

Its portfolio includes DecisionDx-Melanoma, which helps evaluate the risk of metastatic recurrence in patients with cutaneous melanoma; DecisionDx-SCC, which assesses metastatic risk in cutaneous squamous cell carcinoma; and DecisionDx-UM, a test for determining metastatic risk in uveal melanoma.